This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
Conditions
- Adult B-cell Acute Lymphoblastic Leukemia
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Chronic Lymphocytic Leukemia
Interventions
- BIOLOGICAL: ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)
Sponsor
GUSTAVO SALGUERO
Collaborators